Patents Examined by Nizal S. Chandrakumar
  • Patent number: 11149007
    Abstract: Provided herein are piperidine dione compounds having the following structure: wherein RN, R1, R2, R3, R4, L, V, m, and n are as defined herein, compositions comprising an effective amount of a piperidine dione compound, and methods for treating or preventing an androgen receptor mediated disease.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: October 19, 2021
    Assignee: Celgene Corporation
    Inventors: Massimo Ammirante, Sogole Bahmanyar, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Evan J. Horn, Timothy S. Kercher, Christopher Mayne, Mark A. Nagy, Rama Krishna Narla, Surendra Nayak, Stephen Norris, Patrick Papa, Veronique Plantevin-Krenitsky, John J. Sapienza, Brandon W. Whitefield, Shuichan Xu
  • Patent number: 11149033
    Abstract: The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds represented by formula (I) or formula (II) according to the present invention are remarkably superior in antiviral activity against an influenza virus, and furthermore, have low cytotoxicity and thus low adverse effects on a human body. Therefore, a pharmaceutical composition containing the same as an active ingredient can be effectively used for the prevention or treatment of diseases caused by an influenza virus infection.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 19, 2021
    Assignees: INSTITUT PASTEUR KOREA, ST PHARM CO., LTD.
    Inventors: Ji Young Min, So Young Chang, Ji Hye Lee, Sun Hee Kang, Sun Ju Kong, Su Yeon Jo, Young Mi Kim, Junghwan Choi
  • Patent number: 11147272
    Abstract: Pyridone compounds of formula (1) and salts thereof: wherein R1, R2, R3, X, Y1, Y2, Y3 and n are defined. The pyridone compounds can control plant diseases.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: October 19, 2021
    Assignee: MITSUI CHEMICALS ARGRO, INC.
    Inventors: Hideki Umetani, Hideaki Ikishima, Akihiro Nishida, Shun Okaya, Ryohei Naito, Takeshi Fukumoto, Satoshi Yutani, Toshiaki Ohara
  • Patent number: 11135226
    Abstract: Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: October 5, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11136339
    Abstract: Disclosed are a dihydroartemisinin dimer derivative, a pharmaceutical composition, and an application thereof. The derivative is an artemisinin dimer used for drugs treating or preventing malaria caused by plasmodium, drugs treating autoimmune diseases such as lupus erythematosus, and anti-tumour drugs, which is a pharmaceutical composition prepared from the dihydroartemisinin dimer derivative and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: October 5, 2021
    Assignee: SOUTHEAST UNIVERSITY
    Inventors: Xinsong Li, Ma Si, Longbing Ling
  • Patent number: 11123336
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 21, 2021
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • Patent number: 11123299
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: March 29, 2021
    Date of Patent: September 21, 2021
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Patent number: 11111227
    Abstract: The present disclosure relates to rotigotine behenate, methods for preparing the same and use of the same for treating diseases associated with dopamine receptor. The rotigotine behenate, the structure of which is shown below, is capable of reducing fluctuation in blood drug concentrations, improving the bioavailability of the drug in vivo, and achieving smooth and extended release of rotigotine.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: September 7, 2021
    Assignee: Shandong Luye Pharmaceutical Co., Ltd.
    Inventors: Mina Yang, Yongtao Jiang, Ying Meng, Tao Wang, Qian qian Xu, Xin Shao, Chunjie Sha
  • Patent number: 11091482
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: August 17, 2021
    Assignee: ARDELYX, INC.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell
  • Patent number: 11091643
    Abstract: The present invention is generally directed to the synthesis and use of fluorophores. It is more specifically directed to the synthesis and use of deuterated fluorophores. In one case, the present invention provides a compound of the structure shown in FIG. 44.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: August 17, 2021
    Assignee: Howard Hughes Medical Institute
    Inventors: Luke Lavis, Jonathan B. Grimm
  • Patent number: 11091471
    Abstract: Compounds having the formula (I) wherein R1, R2, R3, R4, R5, R6, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: August 17, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bernd Buettelmann, Giuseppe Cecere, Bernhard Fasching, Katrin Groebke Zbinden, Maria-Clemencia Hernandez, Henner Knust, Andreas Koblet, Emmanuel Pinard, Andrew Thomas
  • Patent number: 11083715
    Abstract: Methods of treatment of addiction and/or dependence, methods of promoting cessation of various addictions, such as smoking and/or vaping, and methods of promoting a reduction in various addictions, such as smoking and/or vaping, uses of cytisine as an addiction cessation treatment, and dosage regimens for the foregoing are provided.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: August 10, 2021
    Assignee: Achieve Life Sciences, Inc.
    Inventors: Cindy A. Jacobs, Daniel F. Cain, Anthony Clarke
  • Patent number: 11083716
    Abstract: Methods of treatment of addiction and/or dependence, methods of promoting cessation of various addictions, such as smoking and/or vaping, and methods of promoting a reduction in various addictions, such as smoking and/or vaping, uses of cytisine as an addiction cessation treatment, and dosage regimens for the foregoing are provided.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: August 10, 2021
    Assignee: Achieve Life Sciences, Inc.
    Inventors: Cindy A. Jacobs, Daniel F. Cain, Anthony Clarke
  • Patent number: 11078184
    Abstract: A dexrabeprazole sodium compound includes crystal forms B and C. The crystal form B has good stability and flowability. The crystal form C is an anhydrous crystal form and has good stability and low hygroscopicity. The crystal forms are suitable for preparing a dexrabeprazole sodium preparation.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: August 3, 2021
    Assignees: JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD., NANJING HAIRUN PHARMACEUTICAL CO., LTD.
    Inventors: Xiangfeng Chen, Hongyu Chen, Xiaoxin Li, Xun Pan, Min Sun
  • Patent number: 11078215
    Abstract: This invention relates to new crystalline forms of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile(lorlatinib) maleate. The invention also relates to pharmaceutical compositions comprising lorlatinib maleate, and to methods of using lorlatinib maleate and compositions comprising it in the treatment of abnormal cell growth, such as cancer, in mammals.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: August 3, 2021
    Assignee: Pfizer Inc.
    Inventor: Klimentina Dimitrova Pencheva
  • Patent number: 11078213
    Abstract: The present invention relates to thienopyrimidine compound, preparation method thereof, pharmaceutical composition and use thereof, and in particular to a type of compounds having ALK and/or c-Met selective inhibitory activity, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with anaplastic lymphoma kinase in vivo, and in the manufacture of a medicament for preventing or treating a disease associated with angiogenesis or cancer metastasis, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: August 3, 2021
    Assignee: HONGYUN BIOTECH CO., LTD.
    Inventors: Xianming Deng, Baoding Zhang, Shuang Liu, Chao Dong, Xihuan Sun, Xiaoxing Huang, Zhou Deng, Yunzhan Li, Yue Lu, Li Li, Zhiyu Hu
  • Patent number: 11072587
    Abstract: Novel compositions and methods for the treatment and prevention of malaria are disclosed herein.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: July 27, 2021
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Debopam Chakrabarti, Ratna Chakrabarti
  • Patent number: 11064698
    Abstract: The present invention provides a compound having excellent control efficacy against pests, especially Lepidoptera pests. A compound represented by formula (1) has excellent control efficacy against pests, especially Lepidoptera pests.
    Type: Grant
    Filed: September 10, 2018
    Date of Patent: July 20, 2021
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Yuta Nagashima, Norio Kimura
  • Patent number: 11059775
    Abstract: Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: July 13, 2021
    Assignees: The Johns Hopkins University, INSTITUTE OF ORGANIC CHEMISTRY & BIOCHEMISTRY
    Inventors: Barbara Slusher, Rana Rais, Jan Vavra, Tomas Tichy, Pavel Majer, Andrej Jancarik, Lukas Tenora
  • Patent number: 11059778
    Abstract: Disclosed herein are novel cannabionid receptor-2 (CB2) agonists and inverse agonists represented by Formula (I), and method of modulating the activity of CB2 by contacting the CB-2 receptor with a compound of Formula (I). Also, disclosed are methods for treating multiple myeloma or osteoporosis in a mammal in need thereof by modulating the activity of a cannabinoid receptor-2 (CB2).
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: July 13, 2021
    Assignee: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Xiang-Qun Xie, Abdulrahman Almehizia, Peng Yang